Head-to-head evidence
ALX2004 vs Ametinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
ALX2004
Developed by ALX Oncology Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07085091 (registry estimate)
Ametinib
Developed by Hansoh Pharmaceutical Group and partners
NCT05754736 · Phase 2 · status unknown
This is a single-arm, open-label study with no comparator group, so there is no way to know whether the combination performs better than existing treatments. Results on tumor response and progression-free survival have not yet been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALX2004's landscape · Ametinib's landscape